Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

BRITTANY WHEELER

Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical

NPI
1639353808
CMS profile
11156556
Location
MESA, AZ

General Payments · PY2024

$1,851.91

  • Reported across 17 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$1,851.91

17 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,851.91 17

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $1,851.91 17

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2024 $1,851.91 17

Payment records · PY2024 (17)

Sorted by paying entity, then date · as published by CMS

Program year 2024
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Takeda Pharmaceuticals U.S.A., Inc. $705.81 10/11/2024 Consulting Fee Undisputed 01/23/2026 1137842756 CMS
Takeda Pharmaceuticals U.S.A., Inc. $225.80 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842758 CMS
Takeda Pharmaceuticals U.S.A., Inc. $139.28 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842760 CMS
Takeda Pharmaceuticals U.S.A., Inc. $197.38 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842762 CMS
Takeda Pharmaceuticals U.S.A., Inc. $122.54 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842764 CMS
Takeda Pharmaceuticals U.S.A., Inc. $33.97 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842766 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.65 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842768 CMS
Takeda Pharmaceuticals U.S.A., Inc. $48.95 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842770 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.65 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842772 CMS
Takeda Pharmaceuticals U.S.A., Inc. $122.54 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842774 CMS
Takeda Pharmaceuticals U.S.A., Inc. $33.97 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842776 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.65 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842778 CMS
Takeda Pharmaceuticals U.S.A., Inc. $48.98 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842780 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.93 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842782 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.25 11/07/2024 Consulting Fee Undisputed 01/23/2026 1137842784 CMS
Takeda Pharmaceuticals U.S.A., Inc. $36.71 11/09/2024 Consulting Fee Undisputed 01/23/2026 1137842786 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.85 11/09/2024 Consulting Fee Undisputed 01/23/2026 1137842788 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2024
Source files
Dataset page · Bulk file · PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.